01 Industry overview
The headhunter pharmaceutical industry at a glance
The pharmaceutical industry is a large, innovation-led market: global net medicine spending reached $487 billion in 2024, while talent demand is supported by ongoing drug approvals, manufacturing investment and M&A.
- $487B[2]
- U.S. net spending, 2024
- 54.8%[82]
- North American market share, 2024
- 46[83]
- Novel FDA drugs approved, 2025
- $143B[84]
- Biopharma M&A value, 2025
- Market size
- IQVIA reported U.S. net medicine spending of $487 billion in 2024. This is a country-level spending measure rather than total global pharmaceutical-industry revenue, so a single comparable global market-size figure is not stated here.[2]
- Forecast & CAGR
- IQVIA forecasts global net medicine spending to increase by $116 billion between 2024 and 2029. The source describes the outlook in absolute dollars rather than providing a single headline CAGR.[85]
- Market share & regions
- North America, defined by EFPIA as the United States and Canada, held 54.8% of the global retail and hospital prescription pharmaceutical market in 2024. Europe, China and Japan followed as the other major regional markets.[82]
- Segmentation
- The FDA reported that 34 of the 46 novel drugs approved in 2025 were new molecular entities and 12 were biologics. Exactly 23 approvals received orphan-drug designation, showing the importance of biologics, small molecules and rare-disease products as industry segments.[83]
- Key players & concentration
- The available sources identify major global pharmaceutical companies and regional concentration, but do not provide a sufficiently comparable current market-share table for calculating the leading companies’ combined share. This field is therefore limited to the documented regional concentration: North America held 54.8% of the market in 2024.[82]
- Pricing
- IQVIA reported that average prescription prices in the United States were flat in 2024, while U.S. out-of-pocket prescription-drug spending reached $98 billion. The combination indicates that spending growth was driven more by utilization and product mix than by average price increases.[2]
- Trends, drivers & challenges
- Growth is being supported by expanded access, increased medicine use and innovative therapies, while pricing pressure, loss of exclusivity and legislative changes are identified as offsets through 2029. Biopharma dealmaking also shifted toward fewer, larger transactions in 2025.[85]
- Consumer behavior & competition
- U.S. prescription-drug spending increased alongside greater use of medicines with significant clinical benefits, while average prescription costs remained flat in 2024. Competition is also shaped by loss of exclusivity and the entry of generic and follow-on products, although no current global competitor-share table was found.[2][85]
- M&A
- Alvarez & Marsal recorded 130 biopharma M&A deals worth $143 billion in 2025, compared with 206 deals worth $79 billion in 2024. The average deal size reached $1.1 billion in 2025, reflecting a market focused on larger strategic transactions.[84]
- Regulation
- The FDA approved 46 novel drugs in 2025, including 34 new molecular entities and 12 biologics. The agency also reported that 32 of the 46 products were approved in the United States before approval in other countries, emphasizing the importance of U.S. regulatory expertise.[83]
02 Ranking
Top 10 Companies in the Headhunter Pharmaceutical Industry
The leading companies in the headhunter pharmaceutical industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 10, 2026 · Next review December 10, 2026
Verdict
Korn Ferry leads Gitnux's 2026 headhunter pharmaceutical ranking with an Overall score of 9.5, with revenue growth 6.43%. Russell Reynolds Associates is the runner-up at 9.2, with revenue growth 4.6%.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in executive search
Korn Ferry
US
Ranked #1 · 9.5 · Executive search
Why we picked it: Global executive search and leadership advisory with 6.43% revenue growth, supporting life-sciences leadership demand.
#2 overall
Russell Reynolds Associates
US
Ranked #2 · 9.2 · Executive search
Why we picked it: Global executive search and leadership advisory; revenue growth of 4.6% aligns with sustained hiring for life-sciences executives.
#3 overall
Heidrick & Struggles
US
Ranked #3 · 9.1 · Executive search
Why we picked it: Executive search for pharmaceutical and life-sciences leadership roles, with operating margin 0.7% documented.
Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.
Full ranking
Sort by
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Korn Ferry Executive search · US | 9.5 | 9.9 | 8.6 | 9.3 | 9.9 | |
Company snapshot · Korn Ferry · Data as of November 10, 2026 Included in the life-sciences executive search top-50 ranking.[15]
| |||||||
| 2 | Russell Reynolds Associates Executive search · US | 9.2 | 9.5 | 8.3 | 8.8 | 9.9 | |
Company snapshot · Russell Reynolds Associates · Data as of November 10, 2026 Listed among influential life-sciences executive search firms.[15]
| |||||||
| 3 | Heidrick & Struggles Executive search · US | 9.1 | 9.2 | 7.6 | 9.3 | 9.9 | |
Company snapshot · Heidrick & Struggles · Data as of November 10, 2026 Provides executive search for pharmaceutical and life-sciences leadership roles.[15]
| |||||||
| 4 | Egon Zehnder Executive search · CH | 9.0 | 9.4 | 8.8 | 9.3 | 9.9 | |
Company snapshot · Egon Zehnder · Data as of November 10, 2026 Included in the specialist life-sciences executive search top-50.[15]
| |||||||
| 5 | ZRG Partners Executive search · US | 8.9 | 8.3 | 9.1 | 9.5 | 8.9 | |
Company snapshot · ZRG Partners · Data as of November 10, 2026 Included in the life-sciences executive search top-50 ranking.[15]
| |||||||
| 6 | DHR Global Global executive search for life sciences · US | 8.9 | 8.2 | 9.1 | 9.5 | 8.9 | |
Company snapshot · DHR Global · Data as of November 10, 2026 Listed among influential life-sciences executive search firms.[15]
| |||||||
| 7 | WittKieffer Executive search for pharmaceutical life sciences · US | 8.9 | 8.0 | 9.6 | 9.6 | 8.0 | |
Company snapshot · WittKieffer · Data as of November 10, 2026 Searches for leaders in pharmaceutical, biotechnology and pharmaceutical-services companies.[86]
| |||||||
| 8 | Stanton Chase Global pharmaceutical executive search · US | 8.6 | 8.5 | 8.8 | 8.7 | 8.0 | |
Company snapshot · Stanton Chase · Data as of November 10, 2026 Covers pharmaceutical executive search across its global life-sciences practice.[87]
| |||||||
| 9 | Barrington James Global pharmaceutical and life-sciences recruitment · GB | 8.2 | 7.0 | 9.3 | 9.3 | 7.0 | |
Company snapshot · Barrington James · Data as of November 10, 2026 Its executive-search practice makes senior pharmaceutical appointments globally.[88]
| |||||||
| 10 | DSG Global Executive search for life sciences and healthcare · US | 7.7 | 8.2 | 7.0 | 7.0 | 8.0 | |
Company snapshot · DSG Global · Data as of November 10, 2026 Included in the life-sciences executive search top-50 ranking.[15]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 10, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 10). Top 10 companies in the headhunter pharmaceutical industry. In Headhunter Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/headhunter-pharmaceutical-industry-statistics/#top-companies
report visual · Comparison
Revenue of the largest headhunter pharmaceutical companies
Korn Ferry leads with $2.9B in annual revenue (group level, converted to USD).
Korn Ferry$2.9B
Heidrick & Struggles$1.2B
Russell Reynolds Associates$1.2B
Egon Zehnder$966M
ZRG Partners$308M
DHR Global$223M
source-verifiedir.kornferry.com · huntscanlon.com2026
03 Trends & forecasts
Top 10 Headhunter Pharmaceutical Industry Trends & Forecasts 2027
What is changing in the headhunter pharmaceutical industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Medicine spending continues rising
High confidenceIQVIA projects global net medicine spending to increase by $116 billion between 2024 and 2029. The growth outlook is supported by greater medicine use, expanded access and innovative therapies, although pricing pressure and loss of exclusivity remain offsets.[89]
Forecast 2027: In 2027, pharmaceutical headhunters should see sustained demand for commercial, market-access, pricing and medical-affairs leaders, with hiring strongest around products entering launch or expansion phases.
02Novel-drug approvals remain elevated
High confidenceThe FDA reported 46 novel drugs approved in 2025, including 34 new molecular entities and 12 biologics. The approval volume supports recurring demand for regulatory, clinical-development, pharmacovigilance and medical-affairs specialists.[83]
Forecast 2027: Approval-linked hiring should remain a core 2027 search category, particularly for senior regulatory and clinical leaders who can move products from pivotal trials through commercialization.
03Rare-disease hiring expands
High confidenceTwenty-three of the FDA’s 46 novel-drug approvals in 2025 received orphan-drug designation. Rare-disease programs create demand for specialists in clinical strategy, natural-history studies, patient recruitment, market access and ultra-specialized commercial models.[83]
Forecast 2027: By 2027, headhunters should expect rare-disease expertise to command a premium, especially for executives combining clinical development with reimbursement and patient-advocacy experience.
04Biopharma M&A becomes larger
High confidenceAlvarez & Marsal recorded 130 biopharma M&A deals worth $143.4 billion in 2025, compared with 206 deals worth $79.1 billion in 2024. The average transaction size therefore increased sharply as buyers prioritized fewer, larger and more de-risked assets.[84]
Forecast 2027: In 2027, executive-search demand should favor integration leaders, portfolio strategists and transaction-experienced executives rather than broad-based hiring across every acquired company.
05China-originated innovation gains ground
Medium confidenceAlvarez & Marsal reported that biopharma in-licensing activity involving China doubled in 2025 from 2024 levels. This increases the value of leaders who can evaluate, license, transfer and develop assets across Chinese and Western regulatory systems.[90]
Forecast 2027: By 2027, cross-border licensing, alliance-management and China regulatory searches should grow, although geopolitical risk will keep demand concentrated in organizations with strong compliance and due-diligence capabilities.
06AI skills spread across R&D
High confidenceMcKinsey found that the availability of AI skills in life-sciences R&D grew 26% from 2023 to 2024, compared with 15% growth in the overall talent pool. AI is also being applied across discovery, clinical development, manufacturing, regulatory review and safety surveillance.[91][92]
Forecast 2027: In 2027, pharmaceutical recruiters should increasingly fill hybrid roles requiring scientific depth plus data, machine-learning or AI-governance skills, rather than recruiting purely technical specialists in isolation.
07Manufacturing talent demand strengthens
Medium confidenceBioSpace’s 2026 employment survey identified manufacturing operations among the most commonly anticipated hiring areas, alongside regulatory affairs and automation or machine learning. Industry reporting also points to continuing investment in advanced modalities and manufacturing capacity.[93]
Forecast 2027: Manufacturing, quality, validation, supply-chain and facilities searches should remain among the most resilient pharmaceutical recruitment segments in 2027, particularly for biologics and advanced therapies.
08Advanced-therapy specialists stay scarce
Medium confidenceIndustry analysis identifies cell and gene therapy, antibody-drug conjugates, radiopharmaceuticals, mRNA and peptide manufacturing as areas requiring specialized capabilities. These modalities involve complex development, scale-up, quality and cold-chain requirements.[94]
Forecast 2027: In 2027, searches for CMC, process-development, quality and supply-chain leaders with commercial advanced-therapy experience should remain difficult and comparatively expensive to close.
09Regulatory expertise remains defensive
High confidenceThe FDA stated that 32 of the 46 novel drugs approved in 2025 were approved in the United States before approval in other countries. This reinforces the importance of U.S. submission strategy, agency interaction and regulatory execution.[83]
Forecast 2027: Regulatory-affairs and quality leadership should remain relatively resilient in 2027, even if discovery or corporate functions experience tighter budgets, because late-stage programs cannot easily defer compliance work.
10Pricing pressure shifts hiring toward access
High confidenceIQVIA reported that U.S. average prescription prices were flat in 2024, while U.S. out-of-pocket prescription-drug spending reached $98 billion. Its outlook also identifies pricing pressure and legislative changes as constraints on growth.[89]
Forecast 2027: In 2027, pharmaceutical companies should continue adding or upgrading market-access, health-economics, outcomes-research and government-affairs leadership to defend reimbursement and demonstrate value.
04 Statistics
Technology & Innovation
AI adoption and candidate matching expand into daily search workflows, while concerns about impersonality persist (40% worried about excessive AI use in 2025).
AI in the headhunter pharmaceutical industry
- 40% of surveyed life-sciences talent specialists worried that excessive AI use could make recruitment impersonal in 2025.[1]
- 86% of surveyed senior life-sciences executives said their companies would deploy AI within two years or less in 2024.[2]
- 31% of surveyed recruitment firms expected search-and-match agents to have the largest future impact on recruiter productivity in 2025.[3]
- 75% of surveyed senior life-sciences executives said their companies had started implementing AI during the two years before the 2024 survey.[2]
- 67% of surveyed life-sciences talent-acquisition professionals identified increased AI usage as a leading 2025 talent-acquisition trend.[1]
- 67% of pharmaceutical talent-acquisition teams use AI for candidate matching and fit in 2026.[4]
Automation in the headhunter pharmaceutical industry
- 63% of smaller life-sciences organizations said recruiting teams should prioritize fully embracing remote or hybrid work in 2023.[5]
- 45% of surveyed life-sciences talent-acquisition leaders spent over half their working hours on administrative tasks that could be automated in 2025.[1]
- 53% of smaller life-sciences organizations said recruiting teams should prioritize pay transparency in 2023.[5]
- 36% of larger life-sciences organizations said recruiting teams should prioritize pay transparency in 2023.[5]
- 32% of smaller life-sciences organizations planned to invest in applicant-tracking systems in 2023, compared with 11% of larger organizations.[5]
- 56% greater likelihood of achieving an average placement time below 20 days was associated with automated candidate screening among surveyed recruitment firms in 2025.[3]
Digital Transformation in the professional and business services sector (sector benchmark)
- 40.4% of EU enterprises in professional, scientific and technical activities used at least one AI technology in 2025.[6]
- 51% of U.S. technology executives reported no increase in performance or profitability from digital-transformation investments during the previous two years.[7]
- 35.51% of EU professional, scientific and technical enterprises using AI applied it to business-administration or management processes in 2025.[6]
- 55% of business-services CEOs identified keeping pace with technology and AI transformation as their greatest concern in PwC’s 2025 global CEO survey.[8]
Technology Adoption in the professional and business services sector (sector benchmark)
- 18.55% of EU professional, scientific and technical enterprises using AI applied it to ICT security in 2025.[6]
- 30.87% of EU professional, scientific and technical enterprises using AI applied it to accounting, controlling or finance management in 2025.[6]
- 22.32% of EU professional, scientific and technical enterprises using AI applied it to research and development or innovation activities in 2025.[6]
- 27.33% of EU professional, scientific and technical enterprises using AI applied it to production processes in 2025.[6]
Cloud Computing in the professional and business services sector (sector benchmark)
- 80.4% of Danish professional, scientific and technical enterprises used cloud computing services in 2023.[9]
- 91.2% of Finnish professional, scientific and technical enterprises used cloud computing services in 2023.[9]
- 90.7% of Australian professional, scientific and technical enterprises used cloud computing services in 2022.[9]
- 77.7% of Dutch professional, scientific and technical enterprises used cloud computing services in 2023.[9]
Big Data in the professional and business services sector (sector benchmark)
- 45.4% of Finnish professional, scientific and technical enterprises conducted big-data analysis in 2023.[9]
- 57.5% of Dutch professional, scientific and technical enterprises conducted big-data analysis in 2023.[9]
- 47.5% of German professional, scientific and technical enterprises conducted big-data analysis in 2023.[9]
- 46.8% of Swedish professional, scientific and technical enterprises conducted big-data analysis in 2023.[9]
IoT in the professional and business services sector (sector benchmark)
05 Statistics
Data & Analytics
Recruiting teams plan analytics for resource allocation, performance tracking, and bias checks, with data quality and integration problems still prominent (50% cite integration challenges in 2024).
Data analytics in the headhunter pharmaceutical industry
- 30% of life sciences recruiting teams planned to use data in 2023 to determine where to invest recruiting resources.[5]
- 37% of life sciences recruiting teams planned to use data in 2023 to track recruiter performance.[5]
- 46% of life sciences recruiting teams planned to use data in 2023 to identify their best sources of hire.[5]
- 28% of life sciences recruiting teams planned to use data in 2023 to check for unconscious bias.[5]
- 32% of life sciences recruiting teams planned to use data in 2023 to forecast hiring.[5]
- 20% of life sciences recruiting teams planned to use data in 2023 to determine the return on investment of recruitment-marketing initiatives.[5]
Data Quality in the professional and business services sector (sector benchmark)
- 67% of supply management organizations said their data quality was better or significantly better than two years earlier in 2024.[10]
- 23% of supply management firms spent at least 21% of their time cleaning data in 2024.[10]
- 87% of enterprise data leaders said traditional rules-based approaches to data quality did not scale to current needs in 2024.[11]
- 49% of supply management organizations reported that their data quality was good or excellent in 2024, based on a survey of more than 121 respondents.[10]
- 95% of enterprise companies with at least $1 billion in revenue had experienced a data-quality issue directly affecting business outcomes in 2024.[11]
- 50% of organizations identified data-quality issues as the biggest challenge affecting their data-integration projects in 2024.[12]
Data Governance in the professional and business services sector (sector benchmark)
- 32% of organizations in the 2024 governance study had a formal governance organization in place, while 68% had none.[13]
- 18.3% of organizations used a data-governance or catalog solution as part of their governance program in 2024.[13]
- 61% of organizations had a dedicated data-governance function in 2024, according to a survey of more than 121 supply management professionals.[10]
- 81% of supply management organizations found their data-governance program useful in 2024.[10]
- 33% of North American organizations had a formal data-governance organization in place in 2024.[13]
- 71% of global organizations reported having a data-governance program in 2024, up from 60% in 2023.[12]
KPIs in the headhunter pharmaceutical industry
- 21% of life sciences recruiting teams tracked top-of-funnel activity in 2022.[5]
- 22% of life sciences recruiting teams tracked time in stage in 2022.[5]
- 13% of life sciences recruiting teams tracked interviewer workload in 2022.[5]
- 52% of life sciences recruiting teams tracked source of hire in 2022.[5]
- 41% of life sciences recruiting teams tracked offer-rejection reasons in 2022.[5]
- 19% of life sciences recruiting teams tracked hiring-manager satisfaction in 2022.[5]
06 Statistics
Strategy & Growth
Firm growth expectations are high for 2026 (94% of recruiting firms surveyed). Life-sciences is identified as a top growth industry by 43.6% of executive-search firms.
Growth in the headhunter pharmaceutical industry
- 572 consultants was Korn Ferry’s average consultant count during fiscal 2024.[14]
- 43.6% of executive-search firms identified healthcare and life sciences as a top growth industry for 2025, according to a recruiter survey.[15]
- $85.9 million was Korn Ferry Executive Search Asia-Pacific’s fiscal-2024 fee revenue.[16]
- $506.9 million was Korn Ferry Executive Search North America’s fiscal-2024 fee revenue.[16]
- 94% of recruiting firms surveyed expected revenue growth in 2026.[15]
- $184.5 million was Korn Ferry Executive Search EMEA’s fiscal-2024 fee revenue.[16]
Differentiation in the headhunter pharmaceutical industry
- 142 points comprised CFRE’s evaluation framework for specialized life-sciences recruitment firms.[17]
- 12% was the weighting for market intelligence in CFRE’s life-sciences recruiting-firm evaluation.[17]
- 7 weighted evaluation domains were used by CFRE to assess life-sciences recruiting firms.[17]
- 18% was the weighting for placement outcomes in CFRE’s life-sciences recruiting-firm evaluation.[17]
- 10% was the weighting for thought leadership in CFRE’s life-sciences recruiting-firm evaluation.[17]
- 20% was the weighting for specialization depth in CFRE’s life-sciences recruiting-firm evaluation.[17]
Mergers and acquisitions in the headhunter pharmaceutical industry
- 1 acquisition of Carrot Recruitment was previously completed by Compass Recruitment Solutions in its life-sciences expansion program.[18]
- 1 acquisition of Hanover Search Partners by ZRG was completed in January 2023, adding life-sciences executive-search expertise.[19]
- 1 acquisition of Carter Schwartz was completed by Compass Recruitment Solutions in 2024 before its merger with Compass Executives.[18]
- 24.3% higher odds of drug shortage within two years were associated with drugs involved in pharmaceutical mergers or acquisitions.[20]
- 2.87 trillion dollars was the value of global merger-and-acquisition activity in 2023, the lowest level in more than a decade.[2]
- 182 pharmaceutical-sector mergers and acquisitions were recorded globally in 2023.[20]
Strategic partnerships in the headhunter pharmaceutical industry
- 20-plus years of executive-search experience are cited by ERAPS for its pharmaceutical and biotechnology regulatory-talent network.[21]
- 21% of Korn Ferry Professional Search & Interim fee revenue in fiscal 2024 came from referrals by its other business lines.[14]
- 3,700-plus executive-search engagement clients were served by Korn Ferry in fiscal 2024.[14]
- 2 board members were placed by LifeSci Search for Atai Life Sciences after the firm began working with the company in 2023.[22]
- 3,600-plus clients were served globally by Korn Ferry Professional Search & Interim in fiscal 2024.[14]
- 1 San Francisco office was opened by LifeSci Search in 2020 as part of its expansion and partnership platform.[23]
07 Statistics
People & Workforce
Search cycle timing and retention rates are used to evaluate execution in life-sciences leadership searches, including 88 days average time to fill.
Hiring in the headhunter pharmaceutical industry
- 33 days is Rokos Group’s average time to produce an approved shortlist for life-sciences executive searches; year not stated.[24]
- 88 days is Rokos Group’s average time to fill a life-sciences executive position; year not stated.[24]
- 500+ leadership positions have been filled by Rokos Group in life sciences and healthcare; year not stated.[24]
Employee retention in the headhunter pharmaceutical industry
- 89% of Keller Executive Search hires were retained after one year; year not stated.[25]
- 98.70% of Hunter International’s scientific placements were retained for at least three years; year not stated.[26]
- 98% of Life Sciences Recruitment placements remain in position after 12 months; the figure refers to 2021 placements.[27]
- 98.94% is Frontline Source Group’s executive placement retention rate in life sciences; year not stated.[28]
- 96% of Rokos Group life-sciences placements were retained; the source does not specify the retention period or year.[24]
Remote Work in the professional and business services sector (sector benchmark)
- About 45% of U.S. professional and business-services workers worked remotely during October 2023–September 2024, including hybrid and fully remote work.[29]
- 62.8% of U.S. professional and business-services employees who could work at home did so during 2024–2025, while 66.0% could work at home.[30]
- 37.21% was the average share of paid workdays performed from home by U.S. professional and business-services employees in January 2025.[31]
- 54% of U.S. professional-services firms reported having at least one paid work-from-home employee in November 2024–January 2025.[32]
Hybrid Work in the professional and business services sector (sector benchmark)
- 27% of U.S. full-time employees worked in a hybrid arrangement in 2025, compared with 12% fully remote and 61% fully on-site.[33]
- 54% of U.S. employees with remote-capable jobs worked in a hybrid arrangement in November 2025.[34]
- Across U.S. professional and business services, 38% of full-time employees worked hybrid schedules during January–April 2025.[35]
- Across U.S. professional and business services, 22% of full-time employees worked fully from home during January–April 2025.[35]
- 61% of U.S. employees with remote-capable jobs preferred hybrid work in November 2025, compared with 33% preferring fully remote work.[34]
Employee Engagement in the professional and business services sector (sector benchmark)
- 32% of U.S. employees were engaged at work in 2025, while 17% were actively disengaged.[34]
- 33% of U.S. employees were engaged at work in 2023, while 16% were actively disengaged.[34]
- 32% of U.S. employees were engaged at work in 2024, while 17% were actively disengaged.[34]
- 34% of U.S. employees were engaged at work in 2022, while 16% were actively disengaged.[34]
DEI in the headhunter pharmaceutical industry
Change Management in the professional and business services sector (sector benchmark)
- Approximately one-third of global business-services organizations had no change-management capability in 2022.[37]
- 17% of transformation teams identified training and development programs as their primary change-management approach in 2024.[38]
- 22% of transformation teams identified communication plans as their primary change-management approach in 2024.[38]
- 16% of global business-services organizations managed change systemically across their initiatives in 2022.[37]
- 21% of transformation teams identified stakeholder-engagement strategies as their primary change-management approach in 2024.[38]
08 Statistics
Customer & Sales
Repeat use and high placement retention are tracked as operational proof points, including 100% repeat business reported for a global life-sciences recruitment network.
Customer retention in the headhunter pharmaceutical industry
- 90% is the reported five-year retention rate for searches led by ZRG Partners’ global life-sciences practice; year not stated, global.[19]
- 93% is the recent placement rate reported by Silberstein International for life-sciences executive search, including pharmaceutical clients; year not stated, Europe and international.[39]
- 97% of placed candidates remain in their roles after the first year through BEC’s life-science and healthcare executive recruiting service; year not stated, United States.[40]
- 98% of placements remain in position after 12 months through Life Sciences Recruitment Ltd., serving pharmaceutical and biotech organizations; year not stated, global.[27]
Customer acquisition in the headhunter pharmaceutical industry
- 10 highly specialized headhunters make up Life Sciences Recruitment Ltd.’s recruiting team for pharmaceutical and biotech clients; year not stated, global.[27]
- 27 countries have received placements from Life Sciences Recruitment Ltd., which serves pharmaceutical and biotech organizations; year not stated, global.[27]
- 11 languages are spoken fluently by Life Sciences Recruitment Ltd.’s team serving pharmaceutical and biotech organizations; year not stated, global.[27]
Customer loyalty in the headhunter pharmaceutical industry
- 88% of The Tolan Group’s clients used its recruiting services more than once each year for five consecutive years; the firm’s profile includes executive recruitment, year not stated, United States.[15]
- 100% repeat business is reported by Life Sciences Recruitment Ltd. for its pharmaceutical and biotech recruitment clients; year not stated, global.[27]
Lead generation in the headhunter pharmaceutical industry
- 50% or more of placements came through candidate referrals over the preceding 12 months at a biotech executive network; year not stated, global.[22]
- 60% of Life Sciences Recruitment Ltd.’s placements were diverse in 2021, indicating the firm’s placement activity across its pharmaceutical and biotech talent network; year 2021, global.[27]
- 30% of the biotech executive network’s database consisted of referred candidates; year not stated, global.[22]
09 Statistics
Marketing & Brand
Recruitment marketing use is measured alongside job-posting signals, including under 3% naming generative AI in 2026 and 21% naming automation or workflow capabilities.
Marketing in the headhunter pharmaceutical industry
- 53% of life sciences talent-acquisition teams used multi-channel recruitment touchpoints in 2023.[5]
- 38% of life sciences talent-acquisition teams allocated budget to recruitment marketing in 2023.[5]
- 40% of larger life sciences organizations said recruiting teams should focus on fully embracing remote or hybrid work in 2023.[5]
- 30% of life sciences talent-acquisition teams used long-term candidate nurture in 2023.[5]
- 46% of life sciences talent-acquisition teams used recruitment events in 2023.[5]
Digital marketing in the headhunter pharmaceutical industry
- Under 3% of life sciences marketing job postings named generative artificial intelligence in 2026.[41]
- Approximately 2,000 life sciences companies were included in the 2026 content-marketing analysis.[41]
- 1,000 life sciences marketing job postings were analyzed for the 2026 hiring-signal study.[41]
- Under 9% of life sciences marketing job postings named artificial intelligence or machine learning in 2026.[41]
- 21% of life sciences marketing job postings named automation or workflow capabilities in 2026.[41]
Branding in the headhunter pharmaceutical industry
- 38% of life sciences talent-acquisition teams used career websites or microsites in 2023.[5]
- 45% of larger life sciences organizations built or maintained talent communities in 2023.[5]
- 38% of life sciences talent-acquisition teams used employment-branding campaigns in 2023.[5]
- 47% of larger life sciences organizations used career websites or microsites in 2023.[5]
- 30% of smaller life sciences organizations used career websites or microsites in 2023.[5]
Influencer Marketing in the professional and business services sector (sector benchmark)
- 78% of B2B influencer-marketing practitioners identify brand awareness and lead generation as their joint top challenges, based on Q1 2026 research.[42]
- 74% of B2B influencers use artificial-intelligence tools to enhance content creation, based on Q1 2026 research.[42]
- 86% of B2B influencer-marketing practitioners and creators prefer co-creating content with brands rather than amplifying finished brand content, based on Q1 2026 research.[42]
- 44% of B2B influencer-marketing practitioners say finding the right talent is their single biggest collaboration obstacle, based on Q1 2026 research.[42]
10 Statistics
Operations & Execution
Time-to-fill and volume of screened candidates anchor performance measurement, with 22 days average pipeline-role fill time in one recruiter-on-demand RPO benchmark.
Process optimization in the headhunter pharmaceutical industry
- 93% was the offer-acceptance rate achieved by a pharmaceutical leader using RPO with a strong candidate-experience focus.[43]
- 40 days or less was Pharma B’s service-level target for time to fill, reviewed monthly and quarterly.[44]
- 692 roles were filled with niche pharmaceutical talent in seven months through a recruiter-on-demand RPO program.[43]
- 4,500+ candidates were pre-screened during a seven-month RPO project for a pharmaceutical company.[43]
- 15,000+ applications were managed by a pharmaceutical leader’s RPO program during a seven-month staffing project.[43]
Operational efficiency in the headhunter pharmaceutical industry
- 22 days was the average pipeline-role fill time achieved by a pharmaceutical leader using recruiter-on-demand RPO.[43]
- 60 days was the hiring-cycle goal set by a multinational pharmaceutical company seeking more efficient recruitment operations in Japan.[43]
- 60 days was Pharma D’s service-level target for field-sales leadership positions.[44]
- 76 days was Pharma B’s average time to start in hub locations in a pharmaceutical talent-acquisition benchmark.[44]
- 31 days was Pharma D’s average time to start across the United States in the pharmaceutical recruiting benchmark.[44]
Quality management in the headhunter pharmaceutical industry
- 12% was the average salary increase received by quality candidates when moving roles in the 2024 biopharma market.[45]
- 510 chief-executive jobs were counted across U.S. pharmaceutical and medicine manufacturing in the federal wage data cited by KORE1.[46]
- 3.3 out of 5 was Pharma B’s average second-year performance rating for new hires.[44]
- 14% was the average bonus received by biopharma quality employees in the previous year in Catalyst’s 2024 salary guide.[45]
- 97% was the historical hiring-manager satisfaction rate for new-hire performance, contribution and onboarding effectiveness reported by one pharmaceutical company.[44]
Supply chain in the headhunter pharmaceutical industry
- 8 years of experience was requested by the typical supply-chain director job in the United States and Canada in 2026.[47]
- 61.3% of clinical-supply roles in the United States and Canada were advertised at director level or above in the September 2026 hiring index.[47]
- 38.7% of clinical-supply roles were advertised below director level in the United States and Canada in September 2026.[47]
- 1.5% of companies hiring buyers requested cold-chain experience in the United States and Canada in 2026.[47]
- 39% of pharmaceutical supply-chain respondents said real-time visibility was a top initiative for shipment-deviation management in 2022.[48]
Outsourcing / Offshoring in the professional and business services sector (sector benchmark)
- 47.5% of EU enterprises sourcing abroad sourced administrative and management functions internationally during 2021–2023.[6]
- 60% of EU business-services enterprises sourcing abroad were in the business-services sector, compared with 40% in industry and construction, during 2021–2023.[6]
- 29% of U.S. CPA firms responding to the 2025 National MAP Survey utilized offshoring, rising to 74% among firms with at least $10 million in net client fees.[49]
- 65% of U.S. CPA firms participating in the 2025 National MAP Survey that offshored used India, followed by 33% using the Philippines.[49]
- 28.8% of EU enterprises sourcing abroad sourced information and communication technology services internationally during 2021–2023.[6]
11 Statistics
Finance & Pricing
Pricing is tracked via retained versus contingency structures and fees, while revenue mix shows 62.88% of executive-search revenue coming from retained searches in 2025.
Pricing strategy in the headhunter pharmaceutical industry
- 10.44% is the projected compound annual growth rate for the life-sciences and healthcare executive-search vertical through 2031.[50]
- 62.88% of global executive-search market revenue came from retained searches in 2025, including life-sciences and healthcare searches.[50]
- 30%–33.3% of compensation is the commonly cited retained-search fee range in the life-sciences recruitment sector.[51]
- $30,000–$100,000 is GeneCoda’s typical total fee range for flat-fee retained life-sciences executive searches.[52]
- 25% of negotiated candidate salary is the average contingency-search fee cited for life-sciences recruitment.[51]
Cost reduction in the headhunter pharmaceutical industry
- 86% of U.S. life-sciences temporary-staffing revenue was represented by the 27 largest firms evaluated in 2023, indicating substantial supplier concentration for procurement programs.[53]
- $3.1 billion was the estimated total U.S. life-sciences temporary-staffing market in 2023.[53]
- 1.5% was Yoh’s estimated share of U.S. life-sciences temporary-staffing revenue in 2023.[53]
- $2.7 billion was generated by 27 U.S. life-sciences temporary-staffing firms in 2023.[53]
- 40% longer than the general market was the reported time required to fill a nonexecutive life-sciences role, at up to approximately 105 days in 2025.[54]
Profitability in the headhunter pharmaceutical industry
- Approximately 150 senior-level healthcare and life-sciences searches are led worldwide by Page Executive each year.[55]
- More than 10% year-on-year growth was reported for LHH executive search revenue in 2025.[56]
- Four to five times annual compensation is the estimated cost of a failed executive hire in life sciences cited by a 2026 recruiting-industry report.[17]
- More than 45% of LHH permanent-recruitment revenue came from management and executive roles in 2025.[56]
- 20× or more is the first-year return on investment that GeneCoda says high-performing life-sciences executive hires can generate relative to search fees.[52]
Financial planning in the headhunter pharmaceutical industry
- 1.9% of all U.S. job postings were life-sciences postings in 2024, supporting workforce-demand forecasting for recruitment firms.[57]
- 35% of surveyed life-science professionals reported submitting more than 51 job applications during their job search in 2024.[1]
- 41% of surveyed life-science professionals identified poor recruiter communication as their biggest job-search challenge in 2024.[1]
- 68,581 unique U.S. life-sciences job postings were published per month on average in 2021–2022, compared with 52,422 in 2023–2024.[57]
- 87% of surveyed life-sciences companies had hired employees at some level during the two years preceding the 2025 workforce survey.[57]
12 Statistics
Product & Service
Market demand shows up in job-advertisement and vacancy indices, including 418,095 U.S. life-sciences job advertisements recorded in Q2 2026.
Product development in the headhunter pharmaceutical industry
- 5,000 unique Massachusetts life-sciences job postings were analyzed for top hard skills from January through June 2025.[58]
- 31.1% year-on-year growth in U.S. research, testing and medical-laboratory job postings was recorded in Q2 2026, supporting pharmaceutical research hiring.[59]
- 18.7% of surveyed U.S. life-sciences companies rated hiring research scientists very difficult in 2023.[60]
- 20.8% year-on-year growth in U.S. pharmaceutical and medicine manufacturing job postings was recorded in Q2 2026, reflecting increased demand for development-related talent.[59]
- 8.1% of surveyed U.S. life-sciences companies rated hiring computational-biology and statistics professionals very difficult in 2025.[60]
Product lifecycle in the headhunter pharmaceutical industry
- 17% of pharmaceutical and healthcare organizations receiving leadership appointments in 2023 were locally owned.[61]
- 50% of pharmaceutical and healthcare leadership appointments involved executive-level positions in 2023.[61]
- 17% of pharmaceutical and healthcare leadership appointments involved senior-management positions in 2023.[61]
- 79% of pharmaceutical and healthcare organizations receiving leadership appointments in 2023 were corporate-owned.[61]
- 3% was the reported management-change rate for the pharmaceutical and healthcare sector in 2023.[61]
After-sales in the headhunter pharmaceutical industry
- 20 times longer was Frontline Source Group’s five-year placement warranty than the 90-day guarantee described as standard in 2026.[28]
- 9 awards were reported by Frontline Source Group from ClearlyRated’s Best of Staffing program through 2026.[28]
- 418,095 U.S. life-sciences job advertisements were recorded in Q2 2026.[59]
- 20.7% year-on-year growth in U.S. life-sciences job advertisements was recorded in Q2 2026.[59]
- 15.1% quarter-on-quarter growth in U.S. life-sciences job advertisements was recorded in Q2 2026, increasing demand for recruitment support.[59]
Value proposition in the headhunter pharmaceutical industry
- 86% of 100 senior life-sciences executives said their companies would deploy artificial-intelligence tools within two years or less.[2]
- 75% of 100 senior life-sciences executives said their companies had started implementing artificial intelligence within the previous two years.[2]
- 4 to 5 times annual compensation was the estimated cost of a failed senior life-sciences hire cited in the 2026 report.[17]
- 15% was the estimated gap by which U.S. life-sciences demand for professionals could exceed supply over the following five years.[17]
- 142 evaluation points were used in the 2026 framework for assessing life-sciences recruiting firms.[17]
13 Statistics
Sustainability & Ethics
ESG-related roles and supplier-audit focus appear as hiring and governance inputs, with 7,811 new ESG-related pharmaceutical jobs posted globally in January 2024.
Sustainability in the headhunter pharmaceutical industry
- 63% of biopharma executives said sustainability was imperative to differentiation and business growth in 2024.[62]
- 33% of late-adopter biopharma companies said regulator relationships had improved because of sustainability efforts in 2024.[63]
- 57% of sustainability-leading biopharma companies worked with suppliers and stakeholders to advocate better sustainability policy and regulation in 2024.[63]
- 64% of biopharma executives said failure to achieve sustainability targets posed a critical business threat in 2024.[62]
- 47% of late-adopter biopharma companies worked with suppliers and stakeholders to advocate better sustainability policy and regulation in 2024.[63]
ESG in the headhunter pharmaceutical industry
- 7,811 new ESG-related pharmaceutical jobs were posted globally in January 2024.[64]
- 60% of life-sciences and pharmaceutical organizations reported publishing a sustainability report.[65]
- 21% of life-sciences and healthcare executives said ESG reporting benefited talent attraction and retention.[66]
- 9,203 ESG-related pharmaceutical jobs were closed globally in January 2024.[64]
- 32% of life-sciences and healthcare executives reported significant progress on sustainability in 2024.[66]
Ethics in the headhunter pharmaceutical industry
- 54% of ethics findings in pharmaceutical and healthcare supplier audits concerned business integrity and fair competition in 2024.[67]
- 26 ethics findings were recorded across pharmaceutical and healthcare supplier audits in 2024, compared with 273 human-rights findings.[67]
- 26 ethics findings represented 1% of pharmaceutical and healthcare supplier audit findings in 2024.[67]
- 46% of ethics findings in pharmaceutical and healthcare supplier audits concerned privacy in 2024.[67]
Circular economy in the headhunter pharmaceutical industry
- 53% of small biopharma companies reported being very or extremely effective at reducing water consumption in 2024.[68]
- 55% of medium-sized biopharma companies reported being very or extremely effective at reducing water consumption in 2024.[68]
- 61% of large biopharma companies reported being very or extremely effective at reducing single-use plastics in 2024.[68]
- 51% of small biopharma companies reported being very or extremely effective at reducing single-use plastics in 2024.[68]
- 64% of large biopharma companies reported being very or extremely effective at reducing water consumption in 2024.[68]
Carbon footprint in the headhunter pharmaceutical industry
- 45% of large biopharma companies reported being very or extremely effective at adopting more sustainable manufacturing processes in 2024.[68]
- 41% of biopharma executives said their companies could track their carbon footprint in 2024.[62]
- 41% of medium-sized biopharma companies reported being very or extremely effective at adopting more sustainable manufacturing processes in 2024.[68]
- 64% was the average reduction in Scope 2 emissions achieved by European pharmaceutical companies between 2019 and 2024.[69]
- 18% was the average reduction in Scope 1 emissions achieved by European pharmaceutical companies between 2019 and 2024.[69]
14 Statistics
Risk, Compliance & Legal
Regulatory and privacy controls affect hiring priorities, including 60% of pharmaceutical regulatory professionals planning an eCTD v4.0 assessment in 2024.
Compliance in the headhunter pharmaceutical industry
- 60% of pharmaceutical regulatory professionals planned an eCTD v4.0 assessment in 2024.[70]
- 11% of surveyed pharmaceutical and biotechnology employers preferred contract regulatory hires in 2024.[71]
- 40 biotechnology and pharmaceutical companies were surveyed after hiring a VP or head of regulatory affairs between April 2022 and December 2023.[21]
- 2 of 20 regulatory vice presidents hired through in-house recruiting were terminated for misrepresenting their technical aptitude.[21]
- More than 66% of pharmaceutical regulatory professionals planned submissions in eCTD v4.0 format.[70]
Risk Management in the professional and business services sector (sector benchmark)
- Seventy-seven percent of professional services firms said better analytics and monitoring were needed to improve fraud response in 2026, globally.[72]
- Fifty-four percent of professional services leaders reported integrated or enterprise-wide risk management in 2026, globally.[72]
- Cybersecurity ranked as the top future risk for professional service firms in Aon’s 2025 global survey.[73]
- Thirty-nine percent of professional services leaders said their organizations’ risk and compliance programs were advanced or leading in 2026, globally.[72]
Cybersecurity in the professional and business services sector (sector benchmark)
- Fifty-five point nine percent of Asia-Pacific small businesses in professional, scientific and technical services reviewed their cybersecurity during the previous six months in 2024.[74]
- Fifty-six percent of professional services leaders reported high or very high confidence in detecting advanced cyber threats in 2026, globally.[72]
- Forty-three percent of UK businesses experienced a cyber breach or attack during the 12 months covered by the 2025–2026 survey.[75]
- Thirty-four percent of professional services respondents reported that sensitive content had been breached seven or more times in 2024, globally.[76]
Data Privacy in the professional and business services sector (sector benchmark)
- Forty-one percent of professional services firms identified new U.S. state data privacy laws as a regulatory priority in 2024, globally surveyed respondents.[76]
- Thirty-four percent of professional services firms identified the GDPR as a regulatory priority in 2024, globally surveyed respondents.[76]
- Fifty-eight percent of privacy professionals said their organizations always or frequently practiced privacy by design when building applications or services in 2026, globally.[77]
- Seventy-two percent of privacy professionals reported using data security as an organizational privacy control in 2026, globally.[77]
Crisis Management in the professional and business services sector (sector benchmark)
- Thirty-one percent of global leaders expressed extreme confidence in their organization’s ability to manage critical events in late 2025.[78]
- Sixty-four percent of general counsel in North America reported greater involvement in business continuity and financial contingency planning in 2024.[79]
- Nearly 40% of surveyed general counsel reported no contingency plan for a cyberattack or supply-chain failure in 2024, globally.[79]
- Twenty-four percent of organizations never tested their business continuity or critical-event management plans in late 2025, globally.[78]
- Fifty percent of organizations reported limited or no formal critical-event management strategy in late 2025, globally.[78]
Governance in the headhunter pharmaceutical industry
- 150 senior-level healthcare and life-sciences searches are led worldwide each year by Page Executive.[55]
- 6 of 48 United States companies hiring a corporate-compliance director said the role reported to the board or audit committee.[47]
- $357,500 was the highest advertised salary for a United States corporate-compliance job in Attaineo’s 2026 dataset.[47]
- 7 of 9 United States companies hiring a head of corporate compliance said the role reported to the board or audit committee.[47]
- 24% of health-industry compliance respondents identified technology skills as a current capability gap.[8]
15 Statistics
Globalization & Expansion
Cross-border and country-specific hiring growth are tracked with regional forecasts, including 15.8% growth in European pharmaceutical hiring forecast for 2026.
Globalization in the headhunter pharmaceutical industry
- 12.3% growth in European life-sciences vacancies was forecast for the United Kingdom in 2026.[80]
- 15.8% growth in European pharmaceutical hiring was forecast for 2026, lifting pharma’s share of drug-safety and clinical vacancies to 44.4%.[80]
- 45% of pharma respondents reported fewer than 100 annual international cross-border relocations in the 2024 survey.[81]
- 73% of pharma respondents had a sustainability strategy covering their whole business and supply chain in the 2024 mobility survey.[81]
- 18% of pharma mobility-program respondents reported no change in mobility activity over the previous two years in the 2024 global survey.[81]
Cultural adaptation in the headhunter pharmaceutical industry
- 31.1% growth in Greater London life-sciences vacancies was forecast for 2026 in the European drug-safety and clinical recruitment market.[80]
- 9% of pharma respondents reported between 501 and 1,000 annual domestic non-U.S. relocations in the 2024 survey.[81]
- Cost-containment strategy was one of the two leading factors reducing pharma mobility activity in the 2024 survey.[81]
- Negative company growth was one of the two leading factors reducing pharma mobility activity in the 2024 survey.[81]
- Company growth was identified as a significant driver of increased mobility by pharma respondents in the 2024 survey.[81]
Supplier management in the headhunter pharmaceutical industry
- 24.2% growth in Astellas vacancies was recorded in the United Kingdom in 2025.[80]
- 58% growth in PSI vacancies was forecast for Europe in 2026.[80]
- 67.6% of European drug-safety and clinical vacancies were expected to come from the 20 largest employers in 2026.[80]
- 38.6% growth in Johnson & Johnson vacancies was recorded in the United Kingdom in 2025.[80]
- 52.9% growth in Lonza vacancies was recorded in the United Kingdom in 2025.[80]
Stakeholder management in the headhunter pharmaceutical industry
- 3.7% growth in London regulatory-affairs vacancies was recorded during the first two months of 2026.[80]
- 31.9% growth in European clinical-study vacancies was forecast for 2026.[80]
- 183% growth in South East England regulatory-affairs vacancies was reported for 2025.[80]
- 26.7% growth in European clinical-development vacancies was forecast for 2026.[80]
- 100% growth in Johnson & Johnson UK regulatory-affairs hiring was reported for 2025.[80]
Distribution channels in the headhunter pharmaceutical industry
- 418,095 U.S. life-sciences job advertisements were recorded in the second quarter of 2026.[59]
- 13.2% quarter-on-quarter growth in U.S. research, testing and medical-laboratory job advertisements was recorded in the second quarter of 2026.[59]
- 20.8% year-on-year growth in U.S. pharmaceutical and medicine manufacturing job advertisements was recorded in the second quarter of 2026.[59]
- 15.1% quarter-on-quarter growth in U.S. life-sciences job advertisements was recorded in the second quarter of 2026.[59]
- 31.1% year-on-year growth in U.S. research, testing and medical-laboratory job advertisements was recorded in the second quarter of 2026.[59]
Key questions about the headhunter pharmaceutical industry
How is the pharmaceutical market growing in the forecast window?
IQVIA forecasts global net medicine spending to increase by $116B between 2024 and 2029.
What technology shifts show up in headhunter activity for 2025–2026?
In 2026, 67% of pharmaceutical talent-acquisition teams use AI for candidate matching and fit. Recruitment firms also expected search-and-match agents to drive recruiter productivity impact in 2025.
Which companies lead the headhunter pharmaceutical industry?
Korn Ferry leads Gitnux's 2026 headhunter pharmaceutical ranking with an Overall score of 9.5, with revenue growth 6.43%. Russell Reynolds Associates is the runner-up at 9.2, with revenue growth 4.6%.
How concentrated is the regional market where recruiting demand is drawn from?
North America held 54.8% of the global retail and hospital prescription pharmaceutical market in 2024.
What hiring demand indicators in the drug pipeline affect executive-search work?
The FDA approved 46 novel drugs in 2025, including 34 new molecular entities and 12 biologics. Exactly 23 approvals received orphan-drug designation, reinforcing demand across rare-disease segments.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, November 10). Headhunter Pharmaceutical Industry Statistics. Gitnux. https://gitnux.org/headhunter-pharmaceutical-industry-statistics
MLA
Samuel Norberg. "Headhunter Pharmaceutical Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/headhunter-pharmaceutical-industry-statistics.
Chicago
Samuel Norberg. 2026. "Headhunter Pharmaceutical Industry Statistics." Gitnux. https://gitnux.org/headhunter-pharmaceutical-industry-statistics.
Sources & references
94 sources cited across this report
- recruiterinformation.pharmiweb.jobs
axios.com
bullhorn.com
assets.phenom.com
lp.gem.com
ec.europa.eu
kpmg.com
pwc.com
oecd.org
utah.ismworld.org
anomalo.com
lebow.drexel.edu
informatica.com
ir.kornferry.com
huntscanlon.com
- financialfilings.com
- recruitingexcellencecenter.com
compassrs.co.uk
zrgpartners.com
aspe.hhs.gov
- eraps.bio
linkedin.com
globenewswire.com
- therokosgroup.com
kellerexecutivesearch.com
- hirecruiting.com
lifescirecruitment.com
frontlinesourcegroup.com
govinfo.gov
bls.gov
fred.stlouisfed.org
bfi.uchicago.edu
policycommons.net
gallup.com
wfhresearch.com
lifescisearch.com
everestgrp.com
- 9062582.fs1.hubspotusercontent-na1.net
- silberstein-international.de
- becsearch.com
- contentrevops.com
spotlight-io.com
randstadenterprise.com
ilr.cornell.edu
- sitescdn.wearevennture.co.uk
- kore1.com
- attaineo.com
ups.com
- incpas.org
mordorintelligence.com
- biohire.org
- genecoda.com
yoh.com
- mcphs.edu
pageexecutive.com
- adeccogroup.it
- bioutah.org
- mhtc.org
- lpages.genecoda.com
- ohiolifesciences.org
- andersonwillinger.com
fiercepharma.com
vertassets.blob.core.windows.net
globaldata.com
forvismazars.com
deloitte.com
pscinitiative.org
cdn.cytivalifesciences.com
efpia.eu
celegence.com
- dennispartners.com
grantthornton.com
aon.com
cpaaustralia.com.au
gov.uk
kiteworks.com
isaca.org
everbridge.com
fticonsulting.com
- vacancysoft.com
cartus.com
pharma.fcio.at
fda.gov
alvarezandmarsal.com
bsmedia.business-standard.com
api.wittkieffer.com
ftp.stantonchase.com
barringtonjames.com
iqvia.com
mckinsey.com
arxiv.org
marketing.biospace.com
panda-int.com
Social media in the headhunter pharmaceutical industry